Atjaunināt sīkdatņu piekrišanu

E-grāmata: Innovations in Pharmaceutical Manufacturing on the Horizon: Technical Challenges, Regulatory Issues, and Recommendations

  • Formāts: 120 pages
  • Izdošanas datums: 08-Apr-2021
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309104982
Citas grāmatas par šo tēmu:
  • Formāts - EPUB+DRM
  • Cena: 68,87 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 120 pages
  • Izdošanas datums: 08-Apr-2021
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309104982
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

In 2002, the U.S. Food and Drug Administration (FDA) launched the Pharmaceutical Quality for the 21st Century Initiative to encourage adoption of innovative technologies that would lead to an agile, flexible pharmaceutical manufacturing sector. The goal was to encourage a transition to manufacturing processes and approaches that could produce high-quality drugs reliably without extensive regulatory oversight. Much progress has been made toward that goal as the industry has developed and advanced new technologies, but more progress is required as recent natural disasters and the coronavirus pandemic have revealed vulnerabilities in supply chains and highlighted the need to modernize pharmaceutical manufacturing further.



At the request of the FDA Center for Drug Evaluation and Research (CDER), Innovations in Pharmaceutical Manufacturing on the Horizon identifies emerging technologies - such as product technologies, manufacturing processes, control and testing strategies, and platform technologies - that have the potential to advance pharmaceutical quality and modernize pharmaceutical manufacturing for products regulated by CDER. This report describes many innovations to modernize the manufacture of drug substances and drug products, to advance new control approaches, and to develop integrated, flexible, and distributed manufacturing networks within 5-10 years.

Table of Contents



Front Matter Summary 1 Introduction 2 Innovations in Manufacturing Drug Substances 3 Innovations in Manufacturing Drug Products 4 New Control Approaches to Enable Quality Assurance and Process Capability 5 Innovations in Integrated, Flexible, and Distributed Manufacturing Networks 6 Advancing Innovation: Observations, Challenges, Opportunities, and Recommendations Appendix A: Biographic Information on the Committee to Identify Innovative Technologies to Advance Pharmaceutical Manufacturing Appendix B: Disclosure of Unavoidable Conflicts of Interest Appendix C: Workshop and Webinar Agendas Appendix D: Innovations in Pharmaceutical Manufacturing Proceeding of a Workshopin Brief Appendix E: Barriers to Innovations in Pharmaceutical Manufacturing Proceeding of a Workshopin Brief
Summary 1(6)
1 Introduction
7(5)
The Pharmaceutical Industry Today and Innovation
7(1)
The Food and Drug Administration and Innovation
8(1)
Statement of Task
8(1)
The Committee's Approach to Its Task
8(1)
Organization of This Report
9(1)
References
9(3)
2 Innovations in Manufacturing Drug Substances
12(11)
Unit Operations
12(2)
Process Intensification
14(3)
Process Innovations That Create New Stream Compositions
17(3)
Overcoming Regulatory Challenges
20(1)
References
20(3)
3 Innovations in Manufacturing Drug Products
23(13)
Innovations in Manufacturing Approaches for Conventional Drug Products
23(3)
Enabling New Forms of Drug Products
26(3)
Enabling New Drug-Product Formulations: Novel Excipients
29(3)
Overcoming Regulatory Challenges
32(1)
References
33(3)
4 New Control Approaches to Enable Quality Assurance and Process Capability
36(12)
Systems
36(1)
Sensors
37(2)
Data Analytics and System Modeling
39(5)
Overcoming Regulatory Challenges
44(1)
References
45(3)
5 Innovations in Integrated, Flexible, and Distributed Manufacturing Networks
48(12)
End-To-End Systems
48(2)
Modular Systems
50(1)
Highly Portable Systems
51(1)
Key Technical Challenges for Innovations
52(3)
Key Regulatory Challenges to Innovations
55(2)
Overcoming Regulatory Challenges
57(1)
References
58(2)
6 Advancing Innovation: Observations, Challenges, Opportunities, and Recommendations
60(12)
Key Manufacturing Innovations
61(2)
The Effect of Product Review and Approval as the Basis of Acceptance and Implementation of Manufacturing Technology
63(1)
The Need for Incentives to Advance Technology Innovation
63(2)
The Need for Global Convergence and Harmonization
65(1)
Post-Approval Changes: Essential for Accelerating Innovation
66(1)
Challenges Within the Sphere of FDA Influence in Supporting and Enabling Innovation
66(2)
Committee Recommendations
68(3)
References
71(1)
APPENDIXES
A Biographic Information On the Committee to Identify Innovative Technologies to Advance Pharmaceutical Manufacturing
72(4)
B Disclosure of Unavoidable Conflicts of Interest
76(1)
C Workshop and Webinar Agendas
77(7)
D Innovations in Pharmacuetical Manufacturing: Proceeding of Aworkhsop---In Brief
84(13)
E Barriers to Innovations in Pharmaceutical Manufacturing: Proceedings of a Workshop---In Brief
97